Alopecia Areata Trial Results, Skin Oncology Top EADV Agenda Alopecia Areata Trial Results, Skin Oncology Top EADV Agenda

Early results from a trial of JAK inhibitors for hair loss will be unveiled at the upcoming dermatology meeting. Specialists will also delve into the adverse skin effects of immunotherapy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news

Related Links:

Authors: Nowicka D, Maj J, Jankowska-Konsur A, Hryncewicz-Gwóźdź A Abstract Introduction: Alopecia areata (AA) is a skin disease of unclear etiology. In AA, topical immunotherapy with diphenylcyclopropenone (DPCP) is considered the most effective treatment; however, the most common therapies give unsatisfactory results. Aim: To assess the efficacy of a topical application of a solution of DPCP based on the intensity, duration and number of exacerbations of AA and to compare the efficacy of two treatment regimens. Material and methods: In this prospective study, 39 patients with AA were enrolled. Gr...
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
AbstractAlopecia areata (AA) severity varies from a single small patch to complete loss of scalp hair, body hair, eyelashes and eyebrows. While 40% of all affected individuals only ever get one patch and will achieve a spontaneous complete durable remission within 6  months, 27% will develop additional patches but still achieve complete durable remission within 12 months and 33% will develop chronic AA. Without systemic treatment, 55% of individuals with chronic AA will have persistent multifocal relapsing and remitting disease, 30% will ultimately develop al opecia totalis and 15% will develop alopecia universal...
Source: Australasian Journal of Dermatology - Category: Dermatology Authors: Tags: Consensus Article Source Type: research
Abstract Alopecia areata (AA) severity varies from a single small patch to complete loss of scalp hair, body hair, eyelashes and eyebrows. While 40% of all affected individuals only ever get one patch and will achieve a spontaneous complete durable remission within 6 months, 27% will develop additional patches but still achieve complete durable remission within 12 months and 33% will develop chronic AA. Without systemic treatment, 55% of individuals with chronic AA will have persistent multifocal relapsing and remitting disease, 30% will ultimately develop alopecia totalis and 15% will develop alopecia u...
Source: The Australasian Journal of Dermatology - Category: Dermatology Authors: Tags: Australas J Dermatol Source Type: research
PMID: 30346328 [PubMed - as supplied by publisher]
Source: Dermatitis - Category: Dermatology Authors: Tags: Dermatitis Source Type: research
Experimental Dermatology, EarlyView.
Source: Experimental Dermatology - Category: Dermatology Authors: Source Type: research
Authors: Brown L, Skopit S Abstract KD is an 8 year-old male patient who presented to our clinic in December 2016 with a history of patchy hair loss for many months duration that was worsening. KD's past medical history was notable for atopic dermatitis, and a positive family history of autoimmune thyroid disease. Upon examination he had well circumscribed areas of hair loss throughout his scalp, with exclamation mark hairs seen on dermoscopy. Eyebrows and eyelashes were intact, no epidermal changes of scale or erythema were noted on the scalp and no palpable lymph nodes were present. He was diagnosed with alopecia...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
This systematic review and meta-analysis uses standardized criteria and prognostic factors to examine the clinical hair regrowth outcomes of contact immunotherapy with diphenylcyclopropenone or squaric acid dibutyl ester for patients with alopecia areata.
Source: JAMA Dermatology - Category: Dermatology Source Type: research
Experimental Dermatology,Volume 0, Issue ja, -Not available-.
Source: Experimental Dermatology - Category: Dermatology Authors: Source Type: research
Conclusion: We found topical Turban PUVAsol to be a very cost-effective and safe treatment option for AA.
Source: International Journal of Trichology - Category: Dermatology Authors: Source Type: research
Immunotherapies are emerging as promising avenues for cancer treatment. The treatment paradigm of immune checkpoint inhibition specifically restores a host ’s ability to recognize and destroy tumors. However, despite their overall promise, a majority of patients do not benefit from treatments. Patients with immunologically “cold” tumors bear mutations rendering immunotherapies ineffective. We previously derived an immune infiltrate recruitment tr anscriptional signature from the hair follicle in alopecia areata (AA), that was controlled by a single network-inferred master regulator (MR), IKZF1.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research
More News: Alopecia | Alopecia Areata | Cancer & Oncology | Dermatology | Health | Immunotherapy | Skin